About tirzepatide
Tirzepatide manufacturers are currently led by the originator, Eli Lilly, which sells it as Mounjaro and Zepbound, while generic developers such as Sandoz have filed US applications. Tirzepatide is a once-weekly injectable peptide that activates both the GIP and GLP-1 receptors. It is used for type 2 diabetes, chronic weight management and obstructive sleep apnea with obesity. Pharmaceutical companies can prepare tirzepatide API, pen and vial dossiers for markets where patents allow. Dossiers are being developed in US ANDA and CTD formats.
Tirzepatide key facts
|
Property |
Tirzepatide |
|---|---|
|
INN |
Tirzepatide |
|
Molecule type |
Synthetic 39-amino-acid peptide with a C20 fatty diacid side chain |
|
Molecular formula / weight |
C225H348N48O68 / 4813.5 g/mol |
|
CAS number |
2023788-19-2 |
|
ATC code |
A10BX16 |
|
Drug class |
Dual GIP and GLP-1 receptor agonist |
|
Brand names |
Mounjaro (diabetes; also obesity outside the US); Zepbound (obesity and sleep apnea, US) |
|
Originator |
Eli Lilly |
|
Dosage forms and strengths |
Single-dose pens, KwikPen and vials: 2.5, 5, 7.5, 10, 12.5 and 15 mg, once weekly |
|
Indications (US) |
Type 2 diabetes; chronic weight management; moderate to severe obstructive sleep apnea with obesity |
|
First approval |
US FDA, 13 May 2022 (Mounjaro) |
|
Other US approvals |
Zepbound for weight management, November 2023; obstructive sleep apnea, December 2024 |
|
India |
Mounjaro launched March 2025 for diabetes and obesity |
|
US generic status |
Patent challenges possible from 13 May 2026; Sandoz ANDAs accepted for review in June 2026 |
|
Patent status |
Patents and exclusivities estimated to run to the late 2030s |
Tirzepatide manufacturers and licensing history
Eli Lilly developed tirzepatide as the first dual GIP and GLP-1 receptor agonist. The FDA approved Mounjaro for type 2 diabetes on 13 May 2022. Zepbound followed for weight management in November 2023 and for obstructive sleep apnea with obesity in December 2024. Tirzepatide crossed USD 10 billion in global sales within two years of launch.
Lilly launched Mounjaro in India in March 2025, where it is indicated for both diabetes and obesity. In the US, compounded versions were widely sold during a shortage, but this ended after the FDA declared the shortage over.
US patent challenges could be filed from 13 May 2026, and the FDA accepted two Sandoz ANDAs for generic tirzepatide autoinjectors for review in June 2026. Other companies, including Biocon, are also developing tirzepatide. Buyers should confirm peptide synthesis capability, impurity profile, device supply, GMP status and freedom to operate before choosing a dossier partner.
Tirzepatide dosage forms and dossier types
Tirzepatide is approved as single-dose pens, multi-dose KwikPens and single-dose vials, in six strengths. Generic developers focus on autoinjectors and vials.
|
Form |
Strengths |
Typical dossier |
Notes |
|---|---|---|---|
|
Tirzepatide single-dose pen |
2.5–15 mg |
US ANDA; CTD |
Reference Mounjaro / Zepbound; device data required |
|
Tirzepatide KwikPen (multi-dose) |
2.5–15 mg |
US ANDA; CTD |
Device-specific |
|
Tirzepatide single-dose vial |
2.5–15 mg |
US ANDA; CTD |
Simpler presentation |
|
Tirzepatide API |
Bulk |
US DMF; EU ASMF |
Synthetic peptide; impurity control is critical |
|
Target market |
Dossier format |
Key requirement |
|---|---|---|
|
United States |
ANDA (eCTD) |
Paragraph IV litigation; peptide sameness and immunogenicity data |
|
European Union |
EU CTD |
Data protection and SPC expiry |
|
India, emerging markets |
National CTD |
Local patent status; cold chain |
Tirzepatide regulatory and patent status
The FDA approved Mounjaro on 13 May 2022, and Zepbound in November 2023, with sleep apnea added in December 2024. Since 13 May 2026, generic companies have been able to file US patent challenges, and Sandoz's ANDAs were accepted for review in June 2026. Lilly's patents and exclusivities are estimated to run into the late 2030s, so US generic launch timing will depend on litigation. Check the FDA Orange Book and national patent registers before planning a launch.
Tirzepatide mechanism of action and therapeutic use
Tirzepatide activates both the GIP and GLP-1 receptors. This increases insulin release when blood sugar is high, reduces glucagon, slows stomach emptying and reduces appetite. It is injected once weekly, starting at 2.5 mg and increasing gradually. Tirzepatide is used for type 2 diabetes, chronic weight management and obstructive sleep apnea with obesity.
Tirzepatide licensing and sourcing
Tirzepatide suppliers and licensing partners typically offer dossier development, API supply or device partnerships, timed for patent expiry. Buyers usually compare GMP status, peptide manufacturing capability, device supply, patent position and territory availability. Current offers and supplier contacts are listed among the tirzepatide manufacturers on Pipelinepharma.
Frequently asked questions about tirzepatide
Who are the main tirzepatide manufacturers? Eli Lilly is the originator and sells tirzepatide as Mounjaro and Zepbound. Generic developers include Sandoz, whose US applications were accepted for review in June 2026.
Is there a generic version of tirzepatide? No generic is approved yet. The FDA accepted Sandoz's ANDAs for review in June 2026, but launch timing depends on patent litigation.
What is the difference between Mounjaro and Zepbound? They contain the same drug. In the US, Mounjaro is approved for type 2 diabetes, and Zepbound for weight management and sleep apnea with obesity.
What forms and strengths of tirzepatide are available? Tirzepatide is available as once-weekly pens, KwikPens and vials in 2.5, 5, 7.5, 10, 12.5 and 15 mg strengths.
How is tirzepatide different from semaglutide? Semaglutide activates only the GLP-1 receptor. Tirzepatide activates both the GIP and GLP-1 receptors.
Popular Searches
Want unlimited access to the Pipelinepharma database?
Become a subscriber to unlock:
-
Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.
-
Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.
-
Higher profitability: compare multiple supplier offers and secure the best commercial terms.
-
Expanded network: view supplier portfolios and stay updated on new products.
-
Value-added product ideas: discover products with lower competition potential.
-
Access to marketing authorizations for sale: find already registered products in your target markets.